Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 3 · 100%

Tumour response · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with anti‐CTLA4 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 2.47 [2.01, 3.04]
1465 participants
High

Tumour response · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 3.42 [2.38, 4.92]
1367 participants
High

Tumour response · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies with leads to higher tumour response compared with without anti‐PD1 monoclonal antibodies (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 3.5 [2.07, 5.92]
738 participants
High